Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance

Reuters

2025/11/13

<a href="https://laohu8.com/S/ZURA">Zura Bio</a> reports third quarter net loss of $20.0 million on $139.0 million cash balance

Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113296574) on November 13, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583561656"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583561656\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583561656?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583561656","market":"nz","top_or_hot":-1,"title":"Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZURA\">Zura Bio</a> reports third quarter net loss of $20.0 million on $139.0 million cash balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113296574) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZURA\">Zura Bio</a> reports third quarter net loss of $20.0 million on $139.0 million cash balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113296574) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLbLCrWN:1","article_id":"2583561656","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583561656","pubTimestamp":1763033432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ZURA":"Zura Bio"},"translate_title":"Zura Bio报告第三季度净亏损2000万美元，现金余额为1.39亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZURA":0.9},"content_text":"Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance\n    \n\n        Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113296574) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}